Home » Newsletters » BioWorld Science

BioWorld Science

Dec. 17, 2018

View Archived Issues

Discovery and characterization of novel spirocyclic sigma receptor ligands

miR-335 delivery by extracellular vesicles restores tumor suppressor activity in breast cancer model

Phase II data for ruxolitinib in PTCL and CTCL enriched for JAK/STAT pathway alterations

Lilly initiates phase I study of LY-3454738 for atopic dermatitis

Anergis completes proof-of-concept study of second-generation COP allergy vaccines

XEN-901 shows promise in preclinical and first-in-human studies

Synthetic astaxanthin derivative shows promise in the treatment of amyotrophic lateral sclerosis

Takeda presents first-in-human data for TAK-653

Eli Lilly presents phase II data from nextMONARCH 1 study

Novel class of antibacterial compounds targeting the LPS transport system of Gram-negative bacteria

CRISPR activation uses scissors as squeezers

Axovant licenses gene therapies for GM1 and GM2 gangliosidosis from University of Massachusetts

Vaximm initiates phase I/II study of VXM-01 plus avelumab for the treatment of glioblastoma

Taiho Pharmaceutical divulges KDM1A inhibitors

Gut bacteria eat, make neurotransmitter

Oxford University Innovation presents bacterial beta-lactamase inhibitors

Pfizer initiates phase III program for its 20-valent pneumococcal conjugate vaccine

Suzhou Autopharm Biopharmaceutical synthesizes MAP1LC3B inhibitors

Topadur Pharma discloses PDE5A inhibitors

FDA approves Nplate for pediatric patients with immune thrombocytopenia

Trastuzumab biosimilar Herzuma approved by FDA

Janssen Pharmaceuticals and collaborator identify new antivirals for dengue

Vedanta initiates phase II study of VE-303 for recurrent C. difficile infection

FDA clears IND application for BBT-877 for IPF

Valneva begins phase II with VLA-15 for Lyme disease

DSMB recommends continuation of phase III RESOLVE-IT study of elafibranor in NASH

C4X Discovery and Horizon Discovery establish target discovery partnership

FDA approves Motegrity for adults with chronic idiopathic constipation

Concert initiates phase I program with CTP-692 for adjunctive treatment of schizophrenia

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for June 15, 2026.
Microbiota modulates the antidepressant effects of GLP-1 analogues
BioWorld Science
Liraglutide, a glucagon-like peptide 1 (GLP-1) receptor agonist used in diabetes and obesity, could alleviate depression through a pathway that does not depend on...
Ethyreal launches to treat the underlying cause of Graves’, TED
BioWorld
Ethyreal Bio Inc. has come out of stealth mode in order to disclose preclinical data for ETHY-001, its monoclonal antibody targeting thyroid stimulating hormone...
EHA 2026: With new lenses, a changing view on pediatric cancers
BioWorld
In the most simplistic view, adult cancers occur because “immature cells are exposed to mutagens, accumulate mutations, and across life ultimately transform into...
Enliven’s phase I CML data Enable phase III with BCR/ABL1 bid
BioWorld
Tolerability is a key factor in the appeal of Enliven Therapeutics Inc.’s ELVN-001 for previously treated chronic myeloid leukemia (CML), which yielded positive...